Feniks.Finance is a new financial blockchain based system, created on a fundamentally new concept, capable of scaling its speed as needed and adding new functionality. Feniks.Finance can be used as an international banking system for information transfer and payment execution. The first version of Feniks.Finance will be able to handle payments and storage of users' funds. Namely, the banking transactions labeled in the SWIFT system with MT103 as payment sent and MT202 as a receipt and crediting of the payment to the account. The next step in the development of the system will be a 700 group of SWIFT operations, namely documentary transactions better known as guarantees and letters of credit. The introduction of the 500 group, that is, the operation with securities, suggests that an exchange will appear in our network.

Here at Bithemoth, we strive for excellence and the development of the blockchain world. Through a vigorous and highly intensive process, we selected strong and innovative leaders to become apart of the Bithemoth family and project. Our team stretches across the globe and with a diversity of strengths we will be able to make a huge impact in the blockchain world. Our ecosystem will include: 1. A Decentralized Digital Asset Exchange
 2. Enhanced and Revolutionary Security and Features
 3. A complete Marketplace and Trading Platform
 4. Fully supported ICO incubator
 5. Dedicated Support Systems and Infrastructure
 6. The Development of Brick and Mortar Locations


TrigID is the first and only Internet-based way to show that a real-world human is who they say they are. It enforces "one person, one identity" and you can verify that real-world identity with real-world identifiers like driver's license numbers, SSN's, addresses, phone numbers... All without giving anyone those identifiers.

Emrify is launching a decentralized Personal Health Record platform on top of the Ethereum public blockchain to deliver trusted health information to the right hands at the right time anywhere in the world. With years of building consumer engagement mobile apps, Emrify is laser focused on collecting and locking up data for each person for complete ownership and control to freely share their data. Our top priority is to create attractive cryptoeconomics models to incentivize health data sharing for all parties. With strategic US partnerships with hospitals and doctors, Emrify is building on top of established prototypes to accelerate the launch of production interfaces to firmly establish the Utility Token in healthcare.

INVERSE is a DeFi based platform that provides an array of smart-contract features with integrated time-based options. Users have the opportunity to speculate on the drop in value of a suite of Defi coins by utilizing the multiple 'tracking vaults' on the platform. XIV, the protocol's native token, is used to unlock these vaults, and then staked within these vaults for no more than 7 days. As their name implies, these vaults track the real-time price movements of select DeFi tokens (i.e. COMP, AAVE, UNI, YFI). After 7 days, if the value of the DeFi asset being tracked has dropped by a certain percentage, the user will gain a significant percentage yield on the amount of XIV held within the tracking vault. If the price of the DeFi asset does not drop in value beyond the predetermined percentage by the end of the 7-day staking period, the user will forfeit a portion of their staked XIV. Rewards will be automatically disbursed to the user’s web3 browser wallet at the end of the 7-day staking period. Ultimately, INVERSE offers users the option to hedge against the volatility of select crypto assets.

MediLOT is a health data protocol that aims to solve the concerns of Electronic Health Records (EHR). Current EHR systems are fragmented, centralised and lack patient ownership. Through a dual blockchain solution, MediLOT incorporates Artificial Intelligence capabilities onboard its control and data layers which allows the equitable sharing of health data. The MediLOT ecosystem will consist of patients, healthcare providers, researchers and commercial companies.